At GSK, we unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.

Corporate governance

Contents

Strategic report	
Ahead Together	01
2023 performance and key	
performance indicators	02
Chair's statement	04
CEO's statement	06
Business model	08
Our external environment	10
Prevention	13
Our culture and people	14
Research and development	16
Commercial operations:	31
Performance: Vaccines	33
Performance: Specialty Medicines	37
Performance: General Medicines	40
Operations: Manufacturing	
and supply	43
Responsible business	45
Risk management and disclosure	
statements	57
2023 principal risks summary	59
Climate-related financial	
disclosures	62
Nature-related financial disclosures	70
Non-financial and sustainability	
information statement	75
Employees by gender	75
Viability statement	76
Group financial review	77

The Board and GSK Leadership			
Team	108		
Chair's governance statement Corporate governance architecture Ahead Together – Board oversight	114 116 119		
		Continuous engagements and key	
		decisions Board committee reports Remuneration Committee Chair's annual statement Annual report on remuneration	121 128 139 142
Directors' report	161		
Financial statements			
Directors' statement			
of responsibilities	164		
ndependent auditor's report	166		
Financial statements	180		
Notes to the financial statements	184		
Financial statements of GSK plc			
orepared under UK GAAP	267		

Investor information	
Financial record	273
Product development pipeline	277
Products, competition	
and intellectual property	281
Principal risks and uncertainties	284
Share capital and control	295
Dividends	297
Financial calendar 2024	298
Annual General Meeting 2024	298
Tax information for shareholders	299
Shareholder services and contacts	301
US law and regulation	303
Group companies	306
Glossary of terms	315

Cautionary statement

See the inside back cover of this document for the cautionary statement regarding forward-looking statements.

Non-IFRS measures

We use a number of adjusted, non-International Financial Reporting Standards (IFRS) measures to report the performance of our business. Total reported results represent the Group's overall performance under IFRS. Adjusted results and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. Adjusted results and other non-IFRS measures are defined on pages 82 and 83 and reconciliations to the nearest IFRS measures are on pages 93 to 95.